Primary Site >> Pancreatic Cancer
Gene >> PIK3CA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2. PMID: 10490823 |
Ref: Frequent mutation of the PIK3CA gene in ovarian and breast cancers. PMID: 15837735 |
Ref: PIK3CA mutations in intraductal papillary mucinous neoplasm/carcinoma of the pancreas. PMID: 16778113 |
Ref: PIK3CA cancer mutations display gender and tissue specificity patterns. PMID: 18022911 Ref: PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. PMID: 18343945 Ref: Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. PMID: 18413752 Ref: AKT1(E17K) in human solid tumours. PMID: 18504432 |
Ref: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PMID: 19826477 |
Ref: Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. PMID: 20686216 Ref: Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. PMID: 20876794 |
Ref: Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. PMID: 21945955 Ref: GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. PMID: 21998291 |
Ref: Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression. PMID: 22041919 Ref: Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. PMID: 23342270 Ref: Intraductal tubulopapillary neoplasm of the pancreas with somatic BRAF mutation. PMID: 26181322 |
Ref: Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma. PMID: 23450128 Ref: Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. PMID: 23470560 Ref: Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. PMID: 23475955 Ref: Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. PMID: 23893923 Ref: Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. PMID: 24132918 |
Ref: Case report: Intraductal tubulopapillary neoplasm of the pancreas with unique clear cell phenotype. PMID: 24443801 Ref: PIK3CA mutations in mucinous cystic neoplasms of the pancreas. PMID: 24518503 Ref: Valproic acid sensitizes pancreatic cancer cells to natural killer cell-mediated lysis by upregulating MICA and MICB via the PI3K/Akt signaling pathway. PMID: 24885711 Ref: Lentiviral vector-based insertional mutagenesis identifies genes involved in the resistance to targeted anticancer therapies. PMID: 25195596 Ref: PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice. PMID: 25311989 Ref: Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. PMID: 25360116 |
Ref: Molecular landscape of pancreatic cancer: implications for current clinical trials. PMID: 11051691 Ref: Basaloid carcinoma of the pancreas--clinicopathological presentation and oncogenetic snapshot of a rare entity. PMID: 25432630 Ref: Molecular landscape of pancreatic cancer: implications for current clinical trials. PMID: 25714017 Ref: Whole genomes redefine the mutational landscape of pancreatic cancer. PMID: 25719666 Ref: Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. PMID: 25797243 Ref: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. PMID: 26091808 Ref: Diagnostic yield of targeted next generation sequencing in various cancer types: an information-theoretic approach. PMID: 26227479 Ref: A combination of molecular markers and clinical features improve the classification of pancreatic cysts. PMID: 26253305 Ref: PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. PMID: 26436951 Ref: Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature. PMID: 26464736 Ref: A case of MUC5AC-positive intraductal neoplasm of the pancreas classified as an intraductal tubulopapillary neoplasm? PMID: 26586167 Ref: c-Met as a Target for Personalized Therapy. PMID: 26628860 |
Ref: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. PMID: 26350096 Ref: KRAS, BRAF, and PIK3CA mutations, and patient prognosis in 126 pancreatic cancers: pyrosequencing technology and literature review. PMID: 26927447 Ref: Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling. PMID: 26939707 Ref: Therapeutic Benefit of Selective Inhibition of p110alpha PI3-Kinase in Pancreatic Neuroendocrine Tumors. PMID: 27225693 Ref: [New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "a la carte" treatment?]. PMID: 27345450 Ref: Abnormal expression of PTEN and PIK3CA in pemetrexed-resistant human pancreatic cancer cell line Patu8988. PMID: 27525871 Ref: Copy number gain of chromosome 3q is a recurrent event in patients with intraductal papillary mucinous neoplasm (IPMN) associated with disease progression. PMID: 27566563 |
Ref: Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. PMID: 27725226 Ref: Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis. PMID: 28280620 Ref: Insulin Receptor and GPCR Crosstalk Stimulates YAP via PI3K and PKD in Pancreatic Cancer Cells. PMID: 28360038 Ref: A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution. PMID: 28746882 Ref: MicroRNA-217 inhibits cell proliferation, invasion and migration by targeting Tpd52l2 in human pancreatic adenocarcinoma. PMID: 29039566 Ref: Assessment of pancreatic neuroendocrine tumor cytologic genotype diversity to guide personalized medicine using a custom gastroenteropancreatic next-generation sequencing panel. PMID: 29212165 |
Ref: RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1. PMID: 29059158 Ref: Intraductal Tubulopapillary Neoplasm of the Pancreas: An Overview. PMID: 29494224 Ref: Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance. PMID: 29661773 Ref: miR-202 suppresses prostate cancer growth and metastasis by targeting PIK3CA. PMID: 30112070 Ref: Intrapancreatic recurrence of intraductal tubulopapillary neoplasm (ITPN) 16 years after the initial surgery for noninvasive ITPN: a case report. PMID: 30116990 |